Iodide

Iodide

SCHEMBL7956718

CCOC(=O)CN(c1ccc2c(c1)CCCN2C(=O)CCc1ccc(C(=N)N)cc1)S(=O)(=O)c1cccc2cnccc12.I

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
F2 P00734 6/20 0.39
ROCK2 O75116 3/20 0.38
P2RX7 Q99572 7/20 0.36
RORC P51449 1/20 0.35
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
NR3C1 P04150 1/20 0.33
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6979622 0.92 F2 (0.39) F2RORCPDK1PDK2PDK3
SCHEMBL7956920 0.91 F2 (0.46) F2ROCK2P2RX7RORCNR3C1
SCHEMBL6982826 0.90 P2RX7 (0.41) ROCK2P2RX7RORCNR3C1PARP1
SCHEMBL7958921 0.88 F2 (0.52) F2PDK1PDK2PDK3PDK4
SCHEMBL6978633 0.84 RORC (0.36) RORCPDK1PDK2PDK3PDK4
SCHEMBL6985778 0.84 NR3C1 (0.43) F2PDK1PDK2PDK3PDK4
SCHEMBL7958935 0.83 F10 (0.41) F2RORCPDK1PDK2PDK3
SCHEMBL6978671 0.83 F2 (0.46) F2RORCNR3C1PARP1
SCHEMBL6978636 0.81 PDK1 (0.36) RORCPDK1PDK2PDK3PDK4
Iodide SCHEMBL7960633 0.81 F2 (0.41) F2PDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed